Clinical Practice
Antipsychotic Hyperprolactinemia: A PMHNP Protocol
A step-by-step PMHNP protocol for antipsychotic hyperprolactinemia: who to screen, the 4-lab workup, when to image, and when adding 5 mg aripiprazole works.
Read More →
TL;DR — Lithium Monitoring
Lithium remains the gold standard for bipolar maintenance and suicide prevention according to APA practice guidelines, but the 2026 monitoring protocol has evolved. New PMHNPs should narrow the maintenance target to 0.6-0.8 mEq/L (consistent with the FDA-approved lithium labeling). In addition, draw trough levels exactly 12 hours post-dose, and screen every patient for GLP-1 agonist use before starting lithium. Finally, coach hydration and sodium behavior as part of the monitoring plan. This post walks through the complete modern protocol — baseline workup, dosing strategy, draw timing, red flags, and the medication interactions that matter most right now.
In This Guide
Lithium cuts suicide risk in bipolar disorder by roughly 60 percent. No other mood stabilizer comes close. Yet it remains one of the most underprescribed medications in PMHNP practice, largely because new clinicians are afraid of the monitoring.
That fear is backward. The monitoring is what makes lithium safe.
New PMHNPs who understand the 2026 protocol can prescribe lithium confidently. Furthermore, they can catch toxicity before it lands a patient in the ER. As a result, they offer the single most effective long-term bipolar treatment on the market. The ones who avoid it default to second-line agents their patients will cycle through for years.
This is the complete monitoring framework: baseline workup, target ranges, draw timing, and the drug interactions that actually matter. Notably, this matters in an era where a meaningful fraction of bipolar patients are also on a GLP-1 agonist for weight or diabetes.
Why Lithium Monitoring Still Wins in 2026
Lithium remains first-line for bipolar I maintenance in every major international guideline, and the reason is durability. Nothing else reliably reduces suicide risk, and nothing else has a stronger relapse prevention profile over 5 and 10 year windows.
The 2026 Carlat Medication Fact Book reaffirms lithium’s first-line status and notes that combining lithium with a second-generation antipsychotic outperforms either alone in acute mania. For maintenance, lithium monotherapy beats valproate on relapse prevention, hospitalization rate, and suicide outcomes.
Yet prescription rates have fallen for two decades. New PMHNPs tend to reach for lamotrigine or quetiapine first, not because those drugs work better but because the monitoring feels easier. That’s a trap. Patients who should be on lithium end up on three medications that each do part of the job, with more side effects and worse outcomes.
“Avoiding lithium isn’t safer for your patient. It’s safer for you. Once you’ve walked a fellow through two or three lithium starts, the monitoring stops feeling scary and you realize you’re offering something better than anything newer on the market.”
— Lindsay Hill, DNP, PMHNP-BC
The 2026 Lithium Monitoring Baseline Workup
Before the first dose, get a full panel. This is non-negotiable.
Baseline bloodwork includes a BMP (sodium, potassium, BUN, creatinine, eGFR), TSH with free T4, calcium, HbA1c, a urine pregnancy test for anyone of childbearing potential, and a CBC. An ECG is recommended for any patient over 40 or with cardiovascular history.
Document baseline weight and BMI. Lithium can cause 5-10 pounds of weight gain in year one, and you need a baseline to counsel against it. Discuss contraception if relevant — lithium carries Ebstein’s anomaly risk in pregnancy, though lower than once thought.
The 2026 update: screen for GLP-1 agonist use. Ask directly about semaglutide, tirzepatide, or compounded versions. Patients often don’t mention these in a psych intake because they view them as “for weight” not “medication.” A patient on semaglutide who starts lithium is starting two drugs that both affect hydration, gastric emptying, and electrolyte balance. You need to know going in.
Set expectations. Tell the patient: levels check in 5-7 days, again at 2 weeks, again at 1 month, and then every 3-6 months for the life of the prescription. They should know the plan before they swallow the first pill.
Dosing, Timing, and Therapeutic Levels
Start low: 300 mg at bedtime for most adults, 150 mg for patients over 65 or with borderline renal function. Titrate every 3-5 days based on tolerability until you reach the target dose, typically 600-1200 mg total daily.
Target serum levels have narrowed in modern practice. Acute mania targets 0.8-1.2 mEq/L. Maintenance targets 0.6-0.8 mEq/L for most adults and 0.4-0.6 mEq/L for patients over 65. Higher is not better — renal injury risk rises steeply above 1.0 mEq/L sustained over years.
Draw trough levels 12 hours after the last dose, not random. If the patient takes lithium at 9 PM, draw at 9 AM. A level drawn 4 hours post-dose will look toxic when the patient is actually therapeutic. Label the lab order with “trough, 12 hours post-dose” and train the patient to time their draws.
Dose once daily at bedtime when possible. Single-dose nighttime dosing produces the same efficacy as BID dosing with less renal exposure, better adherence, and fewer daytime side effects. The older “TID with meals” protocol is obsolete.
What Most People Get Wrong About Lithium Monitoring
The biggest mistake new PMHNPs make: they monitor lithium like a clinical chemistry problem instead of a hydration problem.
Lithium toxicity rarely shows up because the dose was wrong. It shows up because the patient got the stomach flu, started a new NSAID, went on a GLP-1 agonist, started a diuretic, tried a low-sodium diet, spent a day hiking without water, or had a fever. Every one of those events shifts sodium and water balance, and lithium clearance tracks sodium clearance.
The real protocol is behavioral, not just lab-based. Teach every lithium patient five rules: stay hydrated, don’t start any new medication or supplement without telling you first, call if vomiting or diarrhea lasts more than 24 hours, call if they start a GLP-1 or diuretic, and never try to “cut salt” aggressively.
A patient who understands why they’re checking levels will stay safe. A patient who thinks the level is magic will end up toxic. The monitoring schedule exists to catch trends, but the behavioral coaching prevents the crisis in the first place.
The GLP-1 Agonist Era and Lithium Safety
Roughly one in eight U.S. adults has now tried a GLP-1 agonist. That means a meaningful fraction of bipolar patients on lithium are either already on semaglutide or tirzepatide, or will be started on one during the life of their lithium prescription.
The interaction is not well characterized in package inserts because it’s not a classic pharmacokinetic collision. It’s physiologic. GLP-1 agonists slow gastric emptying, reduce thirst drive, commonly cause nausea and vomiting in the first 8 weeks, and can shift sodium and fluid balance. Every one of those effects can push lithium levels upward.
The protocol: any lithium patient starting a GLP-1 agent needs a level checked at 2 weeks and again at 4 weeks after each dose escalation of the GLP-1. Warn the patient to call immediately if they experience more than 24 hours of vomiting, diarrhea, or inability to keep fluids down. Consider a proactive 10-15 percent lithium dose reduction at the time of GLP-1 initiation for patients already on the upper end of their therapeutic window.
Conversely, any patient on a GLP-1 who starts lithium should be treated as high-risk for toxicity for the first 6 weeks. Check levels weekly.
Frequently Asked Questions
How soon after starting lithium should I check the first level?
Draw the first trough level 5-7 days after starting or any dose change. Lithium reaches steady state in about 5 days, so earlier draws don’t give you usable data. After the first level, repeat at 2 weeks and 1 month, then every 3-6 months if stable.
What serum lithium level is toxic?
Levels above 1.2 mEq/L are the gray zone where toxicity symptoms start. Above 1.5 mEq/L is clearly toxic and requires dose reduction. Above 2.0 mEq/L is a medical emergency — get the patient to an ER for IV fluids and possible dialysis.
Do I still need to check thyroid and kidney function every 6 months?
Yes. Check TSH and a BMP with eGFR every 6 months for the life of the prescription. Lithium-induced hypothyroidism affects roughly 10-15 percent of patients over time and is easy to treat once caught. Renal changes are usually slow but require lifetime surveillance.
Can I prescribe lithium to a patient on NSAIDs?
Yes, with caution. NSAIDs can raise lithium levels by 20-25 percent. If the patient needs chronic NSAID therapy, coordinate with their primary care provider, check a level 1-2 weeks after starting the NSAID, and counsel on hydration. Occasional ibuprofen use is usually fine with patient education.
What do I do if a patient on lithium starts semaglutide?
Check a lithium level at 2 weeks and 4 weeks after starting semaglutide, then after every GLP-1 dose escalation. Warn the patient about GI side effects that could concentrate lithium. Consider a 10-15 percent proactive dose reduction if they’re already near the top of their therapeutic window.
Is lithium safe in pregnancy?
The Ebstein’s anomaly risk is lower than historically feared — roughly 1.2 to 7.7 per 1000 exposed pregnancies versus 1 per 20,000 baseline. For patients with severe bipolar I, the relapse risk of stopping lithium often outweighs fetal risk. This is a shared-decision-making conversation that should involve maternal-fetal medicine.
The Bottom Line
Lithium still has no real competitor for bipolar maintenance and suicide prevention. The 2026 protocol is not more complex than the old one — it’s more physiologic. Check the labs, coach the hydration, screen the GLP-1 use, and draw troughs at the right time. New PMHNPs who master this protocol offer something their patients cannot get from any other medication.
Want hands-on coaching on lithium starts?
The Psych NP Fellowship walks new PMHNPs through psychopharmacology decisions like this one — with mentorship, case-based learning, and live supervision.
This content is for educational purposes and does not replace individualized clinical judgment or supervision.
About the Author
Lindsay Hill, DNP, PMHNP-BC is the founder of the Psych NP Fellowship, a 12-month clinical mentorship program for new and early-career psychiatric nurse practitioners. She is a published contributor to Psychiatric Times, past President of the Arizona APNA Chapter, and co-founder of the Psych NP Network.
Lindsay Hill, DNP, PMHNP-BC is the founder of the Psych NP Fellowship, a 12-month clinical mentorship program for new and early-career psychiatric nurse practitioners. She is a published contributor to Psychiatric Times, past President of the Arizona APNA Chapter, and co-founder of the Psych NP Network.
